Table 1.
Baseline characteristics, categorized by intensity of LLT
| Ezetimibe monotherapy | Statin therapy | Ezetimibe with a statin | Overall | |||
|---|---|---|---|---|---|---|
| Low | Moderate | High | ||||
| Patients, n (%) | 148 (2.5) | 304 (5.0) | 1453 (24.1) | 3836 (63.7) | 284 (4.7) | 6025 (100) |
| Age (years), mean (SD) | 69.0 (10.8) | 71.4 (12.8) | 72.6 (12.0) | 68.6 (12.2) | 68.5 (10.7) | 69.7 (12.2) |
| Sex (Male), % | 82.4 | 74.3 | 73.6 | 78.1 | 79.6 | 77.0 |
| BMI (kg/m2), mean (SD) | 28.8 (3.3) | 28.2 (3.8) | 29.0 (4.2) | 29.0 (4.1) | 29.3 (4.0) | 28.9 (4.1) |
| Charlson comorbidity index, % | ||||||
| 1 | 54.7 | 48.0 | 48.5 | 53.2 | 48.2 | 51.6 |
| 2 | 18.2 | 25.0 | 28.9 | 26.1 | 28.5 | 26.6 |
| 3+ | 27.0 | 27.0 | 22.6 | 20.8 | 23.2 | 21.8 |
| Comorbidities, % | ||||||
| Cardiovascular history (%) | ||||||
| Hypertension | 62.8 | 62.8 | 64.6 | 60.5 | 64.8 | 61.8 |
| Atrial fibrillation | 8.1 | 11.5 | 10.4 | 10.3 | 8.8 | 10.3 |
| Heart failure | 9.5 | 12.8 | 10.8 | 8.7 | 9.5 | 9.5 |
| Stroke | 7.4 | 9.5 | 7.6 | 8.6 | 9.2 | 8.4 |
| Other comorbidities, % | ||||||
| Diabetes | 31.8 | 28.6 | 32.8 | 28.7 | 31.7 | 29.9 |
| Obesity | 19.6 | 20.4 | 20.2 | 23.4 | 21.8 | 22.3 |
| Depression | 10.8 | 9.9 | 11.4 | 9.2 | 10.6 | 9.8 |
| Neoplasia | 10.8 | 11.5 | 9.4 | 8.5 | 9.2 | 8.9 |
| Active smoking | 7.4 | 7.2 | 6.1 | 9.7 | 7.7 | 8.6 |
| Renal failure | 10.8 | 10.5 | 7.8 | 8.1 | 8.5 | 8.2 |
| Statin intolerance | 10.8 | 3.6 | 2.8 | 2.2 | 2.8 | 2.7 |
| Alcoholism | 0.7 | 0.7 | 0.6 | 0.8 | 0.7 | 0.7 |
| Concomitant medications, mean (SD) | 3.5 (1.1) | 3.5 (1.1) | 3.5 (1.2) | 3.5 (1.1) | 3.5 (1.2) | 3.5 (1.1) |
| Concomitant medications, % | ||||||
| Antiplatelet agents | 93.9 | 91.8 | 90.9 | 93.5 | 95.8 | 92.9 |
| Beta-blockers | 76.4 | 78.0 | 77.1 | 81.6 | 77.8 | 80.0 |
| Antithrombotics | 77.7 | 76.0 | 76.2 | 72.8 | 77.1 | 74.1 |
| ARBs | 68.2 | 69.1 | 68.5 | 67.2 | 70.1 | 67.7 |
| Diuretics | 27.7 | 31.6 | 31.3 | 26.8 | 28.9 | 28.2 |
| Antihypertensives | 3.4 | 4.3 | 4.1 | 3.0 | 4.2 | 3.4 |
ARB angiotensin II receptor blockers, BMI body mass index, LLT lipid-lowering therapy, SD standard deviation